Dementia and Alzheimer Disease

Epilepsy

Migraine

Headache and Migraine

MS Advanced Practice Providers

Multiple Sclerosis

NMOSD

MS and Demyelinating Disorders

Parkinson Disease

Movement Disorders

Ataxia

Chronic Inflammatory Demyelinating Polyneuropathy

Muscular Dystrophy

Neuromuscular

Insomnia

Narcolepsy

Sleep Disorders

Stroke

News

Media

All Videos

Medical World News

Podcasts

Weekly Recap

Cure Connections

Insights

News Network

NeurologyLive Peer Exchange

Medcast Podcasts

Medcast Videos

Peers & Perspectives

Roundtable Discussions

Conferences

Conference Coverage

Conference Listing

CME/CE

Partners

Publications

NeurologyLive

Bridging the Gaps

International Journal of MS Care

Resources

Disease Spotlight

Fellows' Corner

Future Leaders in Neurology

Giants of Multiple Sclerosis

Interactive Tools

Live Events

Neurology Resources

Virtual Events

Subscribe

Articles

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 17, 2024. 

NeurologyLive® Friday 5 — May 17, 2024

A panel of experts provided a new update on practice guidelines for prescribing antiseizure medications to patients with epilepsy who may have a pregnancy.

New Published Guidelines Issued for Antiseizure Medications in Patients Seeking Pregnancy

Voyager expects insights from the phase 1a study to inform a subsequent phase 1b trial and anticipates tau PET imaging data in 2026.

Dosing Commenced for Phase 1a Study of Anti-Tau Antibody VY-TAU01 in Alzheimer Disease

Videos

The associate professor in the department of radiology at NYU Langone provided perspective on the unanswered questions regarding neuronal microstructure in migraine following her presentation at the 2024 AAN Annual Meeting. [WATCH TIME: 4 minutes]

Future Research on Neuronal Microstructure Integrity in Migraine Using High-Gradient Diffusion MRI: Katharina Eikermann-Haerter, MD

The associate professor of neurology at Harvard Medical School talked about findings from a recent case series of patients with NMOSD initially on rituximab who then switched to inebilizumab. [WATCH TIME: 4 minutes]

Efficacy of Switching From to Inebilizumab in Rituximab in NMOSD: Michael Levy, MD, PhD

, has been with the team since October 2019. Follow him on Twitter 

Mayo's MOGAD Clinic represents a new type of novel, multidisciplinary care, incorporating multiple different backgrounds of neurology, neuroimmunology, neuro—ophthalmology, and urology, among others.

Building the Archetype for MOGAD Care: Introducing Mayo’s New Clinic

The Consortium of Multiple Sclerosis Centers' 38th Annual Meeting will be held Wednesday, May 29, through Saturday, June 1, 2024 at the Music City Center, in Nashville, Tennessee.

CMSC 2024: What to Expect From This Year's Annual Meeting

Cure SMA introduces tools aiding in SMA clinical trial navigation and participation empowerment.

Cure SMA Unveils Initiatives to Improve Clinical Trial Accessibility

NeurologyLive is your direct connection to the latest neurology news and interviews with expert neurologists in multimedia formats.

About Us

Advisory Board

Editorial

Contact Us

Advertise

Contact MJH LS

Do Not Sell My Information

Terms and Conditions

Privacy

NeurologyLive – Clinical Neurology News and Neurology Expert Insights

Facebook

Twitter

LinkedIN

YouTube

Spotlight

AAN 2024

MDA 2024

ACTRIMS 2024

Treating NMOSD: What's Next?

Clinical Focus

Dementia/Alzheimer

Headache/Migraine

Video Series

1rem

View

Preparing for a New Era in Alzheimer's Disease: Debating New Targeted Biomarkers and Therapeutic Approaches

Clinical

Apolipoprotein E4 in Alzheimer’s Disease

Video content above is prompted by the following question(s):

Discuss the importance of early diagnosis and treatment of Alzheimer’s disease.

Medical experts discuss the criticality of early intervention and evolving treatment strategies surrounding Alzheimer’s disease.

Sharon Cohen, MD, and Marwan Sabbagh, MD, differentiate between the preclinical, prodromal, and dementia stages of Alzheimer's disease (AD), and highlight known risk factors, including the contribution of ApoE gene polymorphism and copy numbers.

Key opinion leaders emphasize the significance of early diagnosis in Alzheimer's disease, as it allows patients to make autonomous decisions and access early treatment options, including potential participation in clinical trials.

Importance of Early Diagnosis of Alzheimer’s Disease

The panel provides an overview of amyloid precursor protein (APP) and the generation of amyloid β (Aβ) peptides, Aβ42 and Aβ40, while also discussing which soluble or insoluble Aβ species (monomers, oligomers, protofibrils, or amyloid plaques) contribute to neuronal damage and the clinical manifestation of Alzheimer's disease.

Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease

Panelists delve into the amyloid cascade hypothesis of Alzheimer's disease and the ongoing debate surrounding it, discussing the presence and potential roles of Aβ monomers, oligomers, protofibrils, and amyloid plaques in patients with Alzheimer's disease.

Amyloid Cascade Hypothesis of Alzheimer’s Disease

Peer Exchange

 Peer Exchange video series features panels of expert physicians engaging in in-depth discussions about practice-changing treatments, challenges in care, and the future paradigm of management for neurologic diseases.

Importance of Early Diagnosis of Alzheimer’s Disease

EP: 1.Apolipoprotein E4 in Alzheimer’s Disease

EP: 2.Importance of Early Diagnosis of Alzheimer’s Disease

EP: 3.Amyloid Precursor Protein and Amyloid Beta Species in Alzheimer’s Disease

EP: 4.Amyloid Cascade Hypothesis of Alzheimer’s Disease